"Oncologists still rely heavily on biological characterisation of tumours and a limited number of biomarkers which have demonstrated clinical utility. Routine cancer diagnostic tools may not be always sensitive enough and may only detect proteins at levels corresponding to an advanced stage of the disease. Recently, new genomic and proteomic molecular tools (molecular signatures) are being employe ...